Viral Vector & Plasmid DNA Manufacturing Market to Grow at a CAGR of 22.1% to reach US$ 2,247.7 Million from 2020 to 2027

Viral Vector & Plasmid DNA Manufacturing Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product (Viral Vectors, Non-viral Vectors); Application (Cancer, Inherited Disorders, Viral Infections, Others), and Geography

Publication Month: Jun 2020 | Report Code: TIPRE00003074 | No. of Pages: 140 | Category: Biotechnology | Status: Published
Covid

The viral vector & plasmid DNA manufacturing market is expected to reach US$ 2,247.7 million by2027 from US$ 459.4million in 2019. The market is estimated to grow with a CAGR of 22.1% from 2020 to 2027.

 

Gene delivery into target cells can be performed using several different vectors. These are broadly classified into viral and non-viral vectors, both of which present benefits and risks. Viral vectors are tools that are commonly used by molecular biologists to deliver genetic material into cells. The non-viral vectors are naked DNA, particle-based, and chemical-based. Driving factors such as growing awareness of gene therapy, increasing prevalence of genetic disorders, and infectious diseases across the world are expected to upsurge the market growth. Additionally,growth in the global healthcare market is likely to have a positive impact on the market in the coming years.

 

Lucrative Regional Viral Vector & Plasmid DNA Manufacturing Market

Lucrative Regional Viral Vector & Plasmid DNA Manufacturing Market

Get more information on this report :

Market Insights

Increasing Prevalence of Genetic Disorders and Infectious Diseases

According to a study published by National Hemophilia Foundation in 2015, an estimated 400,000 people across the globe are suffering from hemophilia. Further, according to a study published by the NIH in 2019, sickle cell anemia affects an estimated 100,000 people in the US. The application of gene therapy for the treatment of viral infections such as herpes simplex viruses, adeno-associated viruses, poxviruses, and retroviruses is expected to drive the adoption of gene therapies as one of the prominent treatment alternatives, which will eventually boost the growth of the viral vectors and plasmid DNA manufacturing market during the forecast period.

Gene therapies with the help of viral vectors are widely recommended for a range of monogenic disorders, such as sickle cell anemia, severe combined immunodeficiency, cystic fibrosis, hemophilia, Duchenne muscular dystrophy, Parkinson’s disease, and Gaucher disease. For instance, in October 2019, a group of researchers at the National Institutes of Health (NIH) developed a new improved viral vector for the treatment of sickle cell anemia. According to the researchers, the new vector is 10 times efficient than already existing viral vectors in the market.

Product Insights

Based on product, the viral vector & plasmid DNA manufacturing market is segmented into viral vectors and non-viral vectors. The viral vectors segment held the larger share of the market in 2019, owing to the factor that these are used in basic research, gene therapy, and vaccine preparation. Moreover, they can be of different types such as retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, and hybrids. Additionally, effective gene delivery, high transfection efficiency, and stable gene expression have made viral vectors a preferred choice for gene transfer. Hence the growing demand is likely to propel the growth of the market at a highest CAGR during the forecast period.

Global Viral Vector & Plasmid DNA Manufacturing Market, by Product– 2019 & 2027

Global Viral Vector & Plasmid DNA Manufacturing Market, by Product– 2019 & 2027

Get more information on this report :


 

End User Insights

Based on end user, the viral vector & plasmid DNA manufacturing market is segmented into cancer, inherited disorders, viral infections, and others. The cancer segment held the largest share of the market in 2019 and the same segment is estimated to register the highest CAGR in the market during the forecast period. The growing prevalence of cancer is likely to grow market at a faster CAGR.

Strategic Insights

Product launch and expansion are commonly adopted by companies to expand their footprint and product portfolio worldwide in order to meet the growing demand. The market players operating in the viral vector & plasmid DNA manufacturing market adopt the strategy of collaboration and partnership to enlarge customer base across the world, which also permits the players to maintain their brand name in the global market.

By Product

  • Viral Vectors
  • Non-Viral Vectors

By Application

  • Cancer
  • Inherited Disorders
  • Viral Infections
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of Asia Pacific
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of Middle East and Africa
  • South and Central America (SCAM)
    • Brazil
    • Argentina
    • Rest of South America

 

Company Profiles

  • Brammer Bio
  • Sanofi
  • FUJIFILM Diosynth Biotechnologies
  • Cell and Gene Therapy Catapult
  • Cobra Biologics
  • FinVector
  • Kaneka Eurogentec S.A.
  • MassBiologics
  • Spark Therapeutics
  • Uniqure

1.             Introduction

1.1       Scope of the Study

1.2       The Insight Partners Research Report Guidance

1.3       Market Segmentation

1.3.1        Global Viral Vector and Plasmid DNA Manufacturing Market – By Product

1.3.2        Global Viral Vector and Plasmid DNA Manufacturing Market – By Application

1.3.3        Global Viral Vector and Plasmid DNA Manufacturing Market – By Geography

2.             Viral Vector and Plasmid DNA Manufacturing Market – Key Takeaways

3.             Research Methodology

3.1       Coverage

3.2       Secondary Research

3.3       Primary Research

4.             Viral Vector and Plasmid DNA Manufacturing – Market Landscape

4.1       Overview

4.2       PEST Analysis

4.2.1        North America – PEST Analysis

4.2.2        Europe – PEST Analysis

4.2.3        Asia Pacific – PEST Analysis

4.2.4        Middle East and Africa (MEA) – PEST Analysis

4.2.5        South and Central America (SCAM) – PEST Analysis

4.3       Expert Opinion

5.             Viral Vector and Plasmid DNA Manufacturing Market – Key Market Dynamics

5.1       Market Drivers

5.1.1        Growing Awareness of Gene Therapy

5.1.2        Increasing Prevalence of Genetic Disorders and Infectious Diseases

5.2       Market Restraints

5.2.1        High Cost Associated with Gene Therapies

5.3       Market Opportunities

5.3.1        Increasing Funding for Gene Therapies

5.4       Future Trends

5.4.1        Integration of Advanced Computing Technologies

5.5       Impact Analysis

6.             Viral Vector and Plasmid DNA Manufacturing Market – Global Analysis

6.1       Global Viral Vector and Plasmid DNA Manufacturing Market Revenue Forecast And Analysis

6.2       Global Viral Vector and Plasmid DNA Manufacturing Market, By Geography - Forecast And Analysis

6.3       Market Positioning of Key Players

7.             Viral Vector and Plasmid DNA Manufacturing Market– By Product

7.1       Overview

7.2       Viral Vector and Plasmid DNA Manufacturing Market Revenue Share, by Product (2019 and 2027)

7.3       Viral Vectors

7.3.1        Overview

7.3.2        Viral Vectors: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027  (US$ Million)

7.4       Non-Viral Vectors

7.4.1        Overview

7.4.2        Non-Viral Vectors: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)

8.             Viral Vector and Plasmid DNA Manufacturing Market Analysis By Application

8.1       Overview

8.2       Viral Vector and Plasmid DNA Manufacturing Market Revenue Share, by Product (2019 and 2027)

8.3       Cancer

8.3.1        Overview

8.3.2        Cancer: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027  (US$ Million)

8.4       Inherited Disorders

8.4.1        Overview

8.4.2        Inherited Disorders: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)

8.5       Viral Infections

8.5.1        Overview

8.5.2        Viral-Infections: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)

8.6       Others

8.6.1        Overview

8.6.2        Others: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)

9.             Viral Vector and Plasmid DNA Manufacturing Market – Geographic Analysis

9.1       North America: Viral Vector and Plasmid DNA Manufacturing Market

9.1.1        Overview

9.1.2        North America: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.1.3        North America: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027  (USD Million)

9.1.4        North America: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027  (USD Million)

9.1.5        North America: Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019& 2027 (%)

9.1.6        US: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.1.6.1      US: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.1.6.2      US: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.1.6.3      US: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.1.7        Canada: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027  (USD Million)

9.1.7.1      Canada: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.1.7.2      Canada: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.1.7.3      Canada: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.1.8        Mexico: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027  (USD Million)

9.1.8.1      Mexico: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.1.8.2      Mexico: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.1.8.3      Mexico: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.2       Europe: Viral Vector and Plasmid DNA Manufacturing Market

9.2.1        Overview

9.2.2        Europe: Viral Vector and Plasmid DNA Manufacturing Market - Revenue and Forecast to 2027  (USD Million)

9.2.3        Europe: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.2.4        Europe: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.2.5        Europe: Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019& 2027 (%)

9.2.6        Germany: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.2.6.1      Germany: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.2.6.2      Germany: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.2.6.3      Germany: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.2.7        UK: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.2.7.1      UK: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.2.7.2      United Kingdom: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.2.7.3      United Kingdom: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.2.8        France: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027  (USD Million)

9.2.8.1      France: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.2.8.2      France: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.2.8.3      France: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.2.9        Spain: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027  (USD Million)

9.2.9.1      Spain: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.2.9.2      Spain: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.2.9.3      Spain: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.2.10     Italy: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.2.10.1    Italy: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.2.10.2    Italy: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.2.10.3    Italy: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.3       Asia Pacific: Viral Vector and Plasmid DNA Manufacturing Market

9.3.1        Overview

9.3.2        Asia Pacific: Viral Vector and Plasmid DNA Manufacturing Market - Revenue and Forecast to 2027 (USD Million)

9.3.3        Asia Pacific: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.3.4        Asia Pacific: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.3.5        Asia Pacific: Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019& 2027 (%)

9.3.6        China: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027  (USD Million)

9.3.6.1      China: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.3.6.2      China: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.3.6.3      China: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.3.7        Japan: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027  (USD Million)

9.3.7.1      Japan: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.3.7.2      Japan: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.3.7.3      Japan: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.3.8        India: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027  (USD Million)

9.3.8.1      India: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.3.8.2      India: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.3.8.3      India: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.3.9        South Korea: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027  (USD Million)

9.3.9.1      South Korea: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.3.9.2      South Korea: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.3.9.3      South Korea: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.3.10     Australia: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027  (USD Million)

9.3.10.1    Australia: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.3.10.2    Australia: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.3.10.3    Australia: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.4       Middle East & Africa: Viral Vector and Plasmid DNA Manufacturing Market

9.4.1        Overview

9.4.2        Middle East & Africa: Viral Vector and Plasmid DNA Manufacturing Market - Revenue and Forecast to 2027  (USD Million)

9.4.3        Middle East & Africa: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.4.4        Middle East & Africa: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.4.5        Middle East & Africa: Viral Vector and Plasmid DNA Manufacturing Market Share by Country – 2019 & 2027, (%)

9.4.6        Saudi Arabia: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027  (USD Million)

9.4.6.1      Saudi Arabia: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.4.6.2      Saudi Arabia: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.4.6.3      Saudi Arabia: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.4.7        UAE: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.4.7.1      UAE: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.4.7.2      UAE: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.4.7.3      UAE: Viral Vector and Plasmid DNA Manufacturing Market, by Action Mechanism, 2018–2027 (USD Million)

9.4.8        South Africa: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027  (US$ Million)

9.4.8.1      South Africa: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.4.8.2      South Africa: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.4.8.3      South Africa: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.5       South and Central America: Viral Vector and Plasmid DNA Manufacturing Market

9.5.1        Overview

9.5.2        South and Central America: Viral Vector and Plasmid DNA Manufacturing Market - Revenue and Forecast to 2027 (US$ Million)

9.5.3        South and Central America: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.5.4        South and Central America: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.5.5        South and Central America: Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019 & 2027 (%)

9.5.6        Brazil: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027  (USD Million)

9.5.6.1      Brazil: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.5.6.2      Brazil: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.5.6.3      Brazil: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

9.5.7        Argentina: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027  (USD Million)

9.5.7.1      Argentina: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

9.5.7.2      Argentina: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)

9.5.7.3      Argentina: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)

10.          Impact of COVID-19 Pandemic on Global Viral Vector and Plasmid DNA Manufacturing Market

10.1    North America: Impact assessment of COVID-19 Pandemic

10.2    Europe: Impact Assessment of COVID-19 Pandemic

10.3    Asia-Pacific: Impact Assessment of COVID-19 Pandemic

10.4    Rest of the World: Impact Assessment of COVID-19 Pandemic

11.          Viral Vector and Plasma DNA Manufacturing Market – Industry Landscape

11.1    Overview

11.2    Growth Strategies Done by the Companies in the Market, (%)

11.3    Organic Developments

11.3.1     Overview

11.4    Inorganic Developments

11.4.1     Overview

12.          Company Profiles

12.1    Sanofi

12.1.1     Key Facts

12.1.2     Business Description

12.1.3     Products and Services

12.1.4     Financial Overview

12.1.5     SWOT Analysis

12.1.6     Key Developments

12.2    FUJIFILM Diosynth Biotechnologies

12.2.1     Key Facts

12.2.2     Business Description

12.2.3     Products and Services

12.2.4     Financial Overview

12.2.5     SWOT Analysis

12.2.6     Key Developments

12.3    BRAMMER BIO (Thermo Fisher Scientific Inc.)

12.3.1     Key Facts

12.3.2     Business Description

12.3.3     Products and Services

12.3.4     Financial Overview

12.3.5     SWOT Analysis

12.3.6     Key Developments

12.4    Cell and Gene Therapy Catapult

12.4.1     Key Facts

12.4.2     Business Description

12.4.3     Products and Services

12.4.4     Financial Overview

12.4.5     SWOT Analysis

12.4.6     Key Developments

12.5    Cobra Biologics

12.5.1     Key Facts

12.5.2     Business Description

12.5.3     Products and Services

12.5.4     Financial Overview

12.5.5     SWOT Analysis

12.5.6     Key Developments

12.6    FinVector

12.6.1     Key Facts

12.6.2     Business Description

12.6.3     Products and Services

12.6.4     Financial Overview

12.6.5     SWOT Analysis

12.6.6     Key Developments

12.7    Kaneka Eurogentec S.A.

12.7.1     Key Facts

12.7.2     Business Description

12.7.3     Products and Services

12.7.4     Financial Overview

12.7.5     SWOT Analysis

12.7.6     Key Developments

12.8    MassBiologics

12.8.1     Key Facts

12.8.2     Business Description

12.8.3     Products and Services

12.8.4     Financial Overview

12.8.5     SWOT Analysis

12.8.6     Key Developments

12.9    Spark Therapeutics, Inc.

12.9.1     Key Facts

12.9.2     Business Description

12.9.3     Products and Services

12.9.4     Financial Overview

12.9.5     SWOT Analysis

12.9.6     Key Developments

12.10 UniQure N.V.

12.10.1   Key Facts

12.10.2   Business Description

12.10.3   Products and Services

12.10.4   Financial Overview

12.10.5   SWOT Analysis

12.10.6   Key Developments

13.          Appendix

13.1    About The Insight Partners

13.2    Glossary of Terms

LIST OF TABLES

Table 1.             North America Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 2.             North America Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 3.             US Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 4.             US Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027  (USD Million)

Table 5.             Canada Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 6.             Canada Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 7.             Mexico Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027  (USD Million)

Table 8.             Mexico Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 9.             Europe Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027  (USD Million)

Table 10.          Europe Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 11.          Germany Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 12.          Germany Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 13.          United Kingdom Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 14.          United Kingdom Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 15.          France Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027  (USD Million)

Table 16.          France Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 17.          Spain Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 18.          Spain Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 19.          Italy Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027  (USD Million)

Table 20.          Italy Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 21.          Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 22.          Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 23.          China Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027  (USD Million)

Table 24.          China Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 25.          Japan Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027  (USD Million)

Table 26.          Japan Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 27.          India Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027  (USD Million)

Table 28.          India Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 29.          South Korea Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 30.          South Korea Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 31.          Australia Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 32.          Australia Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 33.          Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market, by Product– Revenue and Forecast to 2027 (USD Million)

Table 34.          Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market, by Application– Revenue and Forecast to 2027 (USD Million)

Table 35.          Saudi Arabia Viral Vector and Plasmid DNA Manufacturing Market, by Product– Revenue and Forecast to 2027 (USD Million)

Table 36.          Saudi Arabia Viral Vector and Plasmid DNA Manufacturing Market, by Application– Revenue and Forecast to 2027 (USD Million)

Table 37.          UAE Viral Vector and Plasmid DNA Manufacturing Market, by Product– Revenue and Forecast to 2027 (USD Million)

Table 38.          UAE Viral Vector and Plasmid DNA Manufacturing Market, by Action Mechanism – Revenue and Forecast to 2027 (USD Million)

Table 39.          South Africa Viral Vector and Plasmid DNA Manufacturing Market, by Product– Revenue and Forecast to 2027 (USD Million)

Table 40.          South Africa Viral Vector and Plasmid DNA Manufacturing Market, by Application– Revenue and Forecast to 2027 (USD Million)

Table 41.          South and Central America Viral Vector and Plasmid DNA Manufacturing Market, by Product– Revenue and Forecast to 2027 (USD Million)

Table 42.          South and Central America Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 43.          Brazil Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027  (USD Million)

Table 44.          Brazil Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 45.          Argentina Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)

Table 46.          Argentina Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 47.          Organic Developments Done By Companies

Table 48.          Inorganic Developments Done By Companies

Table 49.          Glossary of Terms, Viral Vector and Plasmid DNA Manufacturing Market

 

 

LIST OF FIGURES

Figure 1.           Viral Vector and Plasmid DNA Manufacturing Market Segmentation

Figure 2.           Viral Vector and Plasmid DNA Manufacturing Segmentation, By Region

Figure 3.           Global Viral Vector and Plasmid DNA Manufacturing Market Overview

Figure 4.           Viral Vectors Segment Held Largest Share of Viral Vector and Plasmid DNA Manufacturing Market

Figure 5.           APAC to Show Significant Growth During Forecast Period

Figure 6.           Viral Vector and Plasmid DNA Manufacturing Market, by Geography (US$ Million)

Figure 7.           Global Viral Vector and Plasmid DNA Manufacturing Market – Leading Country Markets (US$ Million)

Figure 8.           Global Viral Vector and Plasmid DNA Manufacturing Market, Industry Landscape

Figure 9.           North America PEST Analysis

Figure 10.        Europe PEST Analysis

Figure 11.        Asia Pacific PEST Analysis

Figure 12.        Middle East & Africa PEST Analysis

Figure 13.        South and Central America (SCAM) PEST Analysis

Figure 14.        Viral Vector and Plasmid DNA Manufacturing Market Impact Analysis of Drivers and Restraints

Figure 15.        Global Viral Vector and Plasmid DNA Manufacturing Market – Revenue Forecast And Analysis – 2019- 2027

Figure 16.        Global Viral Vector and Plasmid DNA Manufacturing Market – By Geography Forecast And Analysis –  2019- 2027

Figure 17.        Market Positioning Of Key Players In Global Viral Vector and Plasmid DNA Manufacturing Market

Figure 18.        Viral Vector and Plasmid DNA Manufacturing Market Revenue Share, by Product (2019 and 2027)

Figure 19.        Viral Vectors: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)

Figure 20.        Non-Viral Vectors: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027  (US$ Million)

Figure 21.        Viral Vector and Plasmid DNA Manufacturing Market Revenue Share, by Product (2019 and 2027)

Figure 22.        Cancer: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)

Figure 23.        Inherited Disorders: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027  (US$ Million)

Figure 24.        Viral-Infections: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)

Figure 25.        Others: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)

Figure 26.        North America: Viral Vector and Plasmid DNA Manufacturing Market, by Key Country – Revenue (2019)  (USD Million)

Figure 27.        North America Viral Vector and Plasmid DNA Manufacturing Market Revenue and Forecast to 2027 (USD Million)

Figure 28.        North America: Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019 & 2027 (%)

Figure 29.        US: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

Figure 30.        Canada: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

Figure 31.        Mexico: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

Figure 32.        Europe: Viral Vector and Plasmid DNA Manufacturing Market, by Key Country – Revenue (2019) (USD Million)

Figure 33.        Europe Viral Vector and Plasmid DNA Manufacturing Market Revenue and Forecast to 2027 (USD Million)

Figure 34.        Europe: Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019& 2027 (%)

Figure 35.        Germany: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

Figure 36.        UK: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

Figure 37.        France: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

Figure 38.        Spain: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

Figure 39.        Italy: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

Figure 40.        Asia Pacific: Viral Vector and Plasmid DNA Manufacturing Market, by Key Country – Revenue (2019) (USD Million)

Figure 41.        Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Revenue and Forecast to 2027 (USD Million)

Figure 42.        China: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

Figure 43.        Japan: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

Figure 44.        India: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

Figure 45.        South Korea: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027  (USD Million)

Figure 46.        Australia: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

Figure 47.        Middle East & Africa: Viral Vector and Plasmid DNA Manufacturing Market, by Key Country – Revenue (2019) (USD Million)

Figure 48.        Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Revenue and Forecast to 2027 (USD Million)

Figure 49.        Middle East & Africa: Viral Vector and Plasmid DNA Manufacturing Market Share by Country – 2019 & 2027, (%)

Figure 50.        Saudi Arabia: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

Figure 51.        UAE: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)

Figure 52.        South Africa: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

Figure 53.        South and Central America: Viral Vector and Plasmid DNA Manufacturing Market, by Key Country – Revenue (2019) (USD Million)

Figure 54.        South and Central America Viral Vector and Plasmid DNA Manufacturing Market Revenue and Forecast to 2027 (USD Million)

Figure 55.        South and Central America: Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019 & 2027 (%)

Figure 56.        Brazil: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

Figure 57.        Argentina: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)

Figure 58.        Impact Of COVID-19 Pandemic in North American Country Markets

Figure 59.        Impact Of COVID-19 Pandemic in European Country Markets

Figure 60.        Impact Of COVID-19 Pandemic in Asia Pacifican Country Markets

Figure 61.        Impact Of COVID-19 Pandemic in Rest of the World Countries Market

Figure 62.        Growth Strategies Done by the Companies in the Market, (%)

The List of Companies - Portable and Wearable Dialysis Devices Market

  1. Brammer Bio
  2. Sanofi
  3. FUJIFILM Diosynth Biotechnologies
  4. Cell and Gene Therapy Catapult
  5. Cobra Biologics
  6. FinVector
  7. Kaneka Eurogentec S.A.
  8. MassBiologics
  9. Spark Therapeutics
  10. Uniqure

 

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the viral vector and plasmid DNA manufacturing market.

 

  • Highlights key business priorities in order to assist companies to realign their business strategies.

 

  • The key findings and recommendations highlight crucial progressive industry trends in the global viral vector and plasmid DNA manufacturing market, thereby allowing players across the value chain to develop effective long-term strategies.

 

  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

 

  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

 

  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

 

TIPRE00003074
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Frequently Asked Questions

Gene delivery into target cells can be performed using several different vectors. These are broadly classified into viral and non-viral vectors, both of which present benefits and risks. Viral vectors are tools that are commonly used by molecular biologists to deliver genetic material into cells. The non-viral vectors are Naked DNA, particle-based, and chemical-based.

Driving factor such as growing awareness of gene therapy and increasing prevalence of genetic disorders and infectious diseases across the world are expected to upsurge the market growth. In addition, growth in the global healthcare market is likely to have a positive impact on the market in the coming years.

The viral vector & plasmid DNA manufacturing market majorly consists of the players such as Brammer Bio, Sanofi, Cardinal Health Inc., FUJIFILM Diosynth Biotechnologies. Cell and Gene Therapy Catapult, Cobra Biologics, FinVector, Kaneka Eurogentec S.A., MassBiologics, Spark Therapeutics, and Uniqure among others.

Pricing